Table 1.
Baseline data and procedural characteristics
| Author | Year | Design | Sample size | CHA2DS2‐VASC Score(Mean ± SD) | HAS‐BLED Score | Anti‐thrombotic therapy | Follow‐up time | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Watchman | ACP/Amulet | Watchman | ACP/Amulet | Watchman | ACP/Amulet | |||||
| Chun | 2013 | Non‐RCT | 40 | 40 | 4.1 ± 1.5 | 4.5 ± 1.8 | 3.1 ± 1.1 | 3.1 ± 1.2 | OAC or DAPT 6 weeks, switch to SAPT | 12 months |
| Cruz | 2013 | Non‐RCT | 10 | 21 | 3.6 ± 0.8 | 3.7 ± 0.8 | 4.7 ± 1.3 | 4.6 ± 1.3 | DAPT 3 months switch to SAPT | 3 months |
| Gafoor | 2013 | Non‐RCT | 26 | 27 | 5.3 ± 1.4 | 5.0 ± 1.5 | NR | DAPT 3−6 months | 12 months | |
| Kim | 2016 | Non‐RCT | 46 | 50 | 4.1 ± 1.7 | 3.6 ± 1.6 | 2.8 ± 1.2 | 2.7 ± 1.3 | OAC or DAPT 6 weeks, switch to DAPT | 22 months |
| Figini | 2016 | Non‐RCT | 66 | 99 | 3.8 ± 1.6 | 4.0 ± 1.7 | 3.4 ± 1.3 | 3.7 ± 1.5 | DAPT 1−3 months switch to SAPT | 15 months |
| Fastner | 2018 | Non‐RCT | 154 | 35 | 4.5 ± 0.1 | 4.0 ± 1.4 | 3.6 ± 0.2 | 3.7 ± 1.0 | OAC + SAPT or DAPT 6 months, switch to DAPT | 6 months |
| Chen | 2019 | Non‐RCT | 36 | 74 | 3.9 ± 1.5 | 3.6 ± 1.5 | 3.8 ± 1.0 | 3.9 ± 1.1 | OAC or DAPT 6 months | 6 months |
| Cheung | 2019 | Non‐RCT | 67 | 77 | 3.9 ± 1.7 | 3.8 ± 1.4 | 2.7 ± 1.1 | 2.8 ± 0.9 | OAC or DAPT 6 weeks, switch to SAPT | 28 months |
| Jakob | 2020 | Non‐RCT | 278 | 340 | 4.4 ± 1.5 | 4.6 ± 1.6 | 3.9 ± 1.0 | 3.9 ± 1.2 | 5.2% OAC, 5.5% DAPT, 89.3% SAPT | 12 months |
| Caroling | 2020 | Non‐RCT | 266 | 266 | 4.5 ± 1.7 | 4.5 ± 1.5 | 3.2 ± 1.0 | 3.2 ± 1.0 | OAC or DAPT 6 months switch to SAPT clopidpgrel | 30 months |
| Davtyan | 2020 | Non‐RCT | 108 | 92 | 3.5 (3−5) | 4 (3–5) | 3 (2−3) | 3 (3−3) | NOAC or NOAC + ASA or DAPT + Warfarin | 12 months |
| Chiu | 2021 | Non‐RCT | 56 | 56 | 4.2 ± 1.4 | 3.9 ± 1.8 | 3.5 ± 1.7 | 3.3 ± 1.9 | OAC + SAPT or DAPT | 28 months |
| Lakkireddy | 2021 | RCT | 944 | 934 | 4.7 ± 1.4 | 4.5 ± 1.3 | 3.3 ± 1.0 | 3.2 ± 1.0 | DAPT or OAC + SAPT 9 months switch to SAPT | 18 months |
| Mansour | 2021 | RCT | 25 | 26 | 3.9 ± 1.27 | 3.9 ± 1.16 | 4.2 ± 0.9 | 4.1 ± 1.2 | NR | 12 months |
| Mohammed | 2021 | Non‐RCT | 113 | 113 | 4 (3−5) | 4 (3–5) | 3 (2−3) | 3 (2−3) | OAC or DAPT 6‐12weeks, switch to SAPT | 6‐8months |
| Rinodivic | 2021 | Non‐RCT | 99 | 125 | 3.5 | 3.3 | 4.1 | 3.9 | OAC or DAPT 3 months switch to SAPT | 4 years |
| Teiger | 2021 | Non‐RCT | 378 | 434 | 4.6 ± 0.1 | 3.2 ± 0.05 | 22.1% OAC, SAPT 33.2%, DAPT 40.4% | 16 months | ||
| Galea | 2022 | RCT | 110 | 111 | 4.4 ± 1.4 | 4.2 ± 1.4 | 3.2 ± 1.0 | 3.1 ± 0.8 | OAC + SAPT or DAPT 3 months switch to SAPT | 45 days |
| Kretzler | 2022 | Non‐RCT | 389 | 93 | 4.1 ± 1.5 | 4.2 ± 1.5 | 3.6 ± 1.1 | 3.3 ± 1.2 | OAC or DAPT 6 weeks, switch to SAPT | 6 weeks |
Abbreviation: NOAC: novel oral anticoagulants.